Your browser is no longer supported. Please, upgrade your browser.
Settings
AUTL Autolus Therapeutics plc daily Stock Chart
AUTL [NASD]
Autolus Therapeutics plc
Index- P/E- EPS (ttm)-1.40 Insider Own3.52% Shs Outstand44.98M Perf Week-4.81%
Market Cap685.46M Forward P/E- EPS next Y-2.86 Insider Trans- Shs Float33.90M Perf Month-8.41%
Income- PEG- EPS next Q-0.76 Inst Own45.07% Short Float2.30% Perf Quarter-42.21%
Sales1.08M P/S635.56 EPS this Y- Inst Trans- Short Ratio6.71 Perf Half Y-51.46%
Book/sh5.91 P/B2.58 EPS next Y-3.60% ROA- Target Price44.00 Perf Year-32.57%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range14.80 - 53.24 Perf YTD-53.59%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-71.37% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low2.97% ATR1.22
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)34.53 Volatility6.35% 7.86%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.52 Prev Close15.71
ShortableYes LT Debt/Eq- EarningsAug 13 BMO Payout- Avg Volume116.15K Price15.24
Recom- SMA20-5.22% SMA50-16.39% SMA200-43.83% Volume59,827 Change-2.99%
May-17-19Reiterated H.C. Wainwright Buy $45 → $41
Oct-24-18Initiated H.C. Wainwright Buy $45
Jul-16-19 10:31AM  Did You Manage To Avoid Autolus Therapeutics's (NASDAQ:AUTL) 26% Share Price Drop? Simply Wall St.
Jun-19-19 08:40AM  Autolus Therapeutics (AUTL) in Focus: Stock Moves 8.5% Higher Zacks
May-28-19 04:55PM  Autolus Therapeutics to Participate in Upcoming Investor Conferences in June GlobeNewswire
May-14-19 06:30AM  Autolus Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress GlobeNewswire +6.48%
06:30AM  Autolus Therapeutics Plc to Host Earnings Call ACCESSWIRE
May-07-19 04:05PM  Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on May 14 GlobeNewswire
Apr-29-19 02:52PM  Is Autolus Therapeutics plc (AUTL) A Good Stock To Buy? Insider Monkey
Apr-23-19 07:49AM  Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO3 for Treatment of Acute Lymphoblastic Leukemia GlobeNewswire
Apr-15-19 04:02PM  Autolus Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional American Depositary Shares GlobeNewswire +7.20%
03:29PM  What Kind Of Shareholder Owns Most Autolus Therapeutics plc (NASDAQ:AUTL) Stock? Simply Wall St.
Apr-12-19 08:50AM  Autolus Therapeutics (AUTL) Catches Eye: Stock Jumps 5.6% Zacks
Apr-10-19 09:19PM  Autolus Announces Pricing of Public Offering GlobeNewswire -9.16%
Apr-08-19 04:40PM  Autolus Announces Proposed Public Offering in the United States GlobeNewswire
Apr-01-19 02:29PM  Arix Bioscience plc - Autolus Presents Initial AUTO1 Data at AACR PR Newswire
01:05PM  Initial Results from Autolus Therapeutics ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia Presented at the AACR Annual Meeting GlobeNewswire
Mar-29-19 04:05PM  Arix Bioscience plc - Autolus Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019 PR Newswire
04:03PM  Autolus Therapeutics Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019 GlobeNewswire
Mar-26-19 06:00AM  Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day GlobeNewswire +7.89%
Mar-07-19 04:05PM  Autolus Therapeutics to Host R&D Day on March 26, 2019 GlobeNewswire
Mar-04-19 04:05PM  Autolus Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference GlobeNewswire
06:30AM  Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire
Feb-25-19 06:15AM  Vineti announces strategic partnership with Autolus Therapeutics to support delivery of novel T cell therapies GlobeNewswire
06:00AM  Autolus Therapeutics Reports Financial and Operational Results for the Transition Period from October 1 to December 31, 2018 PR Newswire
Feb-21-19 06:30AM  Autolus Therapeutics to Announce Financial Results for the Transition Period from October 1, 2018 to December 31, 2018 and Host Conference Call on February 25, 2019 PR Newswire
Feb-19-19 09:08AM  Arix Bioscience plc: Autolus Announces Updated Results From CARPALL Trial PR Newswire
06:30AM  Autolus Therapeutics Announces Updated Results from Ongoing CARPALL Trial of Pediatric Acute Lymphoblastic Leukemia Presented at the EHA 1st European CAR T Cell Meeting in Paris PR Newswire
Jan-16-19 09:05AM  Alexandria Fully Leases New Built-to-Suit Facility to Autolus Zacks
Jan-14-19 08:28AM  Biotech to create 170 jobs, invest $28M in new Rockville HQ American City Business Journals -5.51%
07:55AM  Autolus Therapeutics Enters Lease with Alexandria Real Estate Equities, Inc. for Future Commercial-Scale Manufacturing Site and U.S. Headquarters PR Newswire
Jan-09-19 07:02PM  MoCo economic development officials plan satellite office in Boston American City Business Journals
12:20PM  London biotech firm planning new U.S. HQ, research facility in Rockville American City Business Journals
Dec-20-18 04:32PM  Autolus Therapeutics to Join NASDAQ Biotechnology Index PR Newswire
Dec-03-18 03:27AM  Arix Bioscience plc: Autolus Announces Update on AUTO4 and AUTO5 Programmes PR Newswire +5.54%
03:25AM  Arix Bioscience plc: Autolus Presents Initial AUTO3 Clinical Data at ASH PR Newswire
Dec-02-18 11:01AM  Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting PR Newswire
Dec-01-18 09:16PM  Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL) PR Newswire
Nov-23-18 08:30AM  Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F PR Newswire
Nov-02-18 07:42AM  Autolus Therapeutics to Present New Data at the ASH Annual Meeting PR Newswire
Nov-01-18 09:10AM  Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 60th ASH Annual Meeting PR Newswire +10.53%
Oct-30-18 08:30AM  Autolus Therapeutics to Present at the Jefferies 2018 London Healthcare Conference PR Newswire
Oct-17-18 08:30AM  Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality PR Newswire
Sep-27-18 08:20PM  UK biotech raises bumper $2 billion, despite Brexit blues Reuters +7.12%
Aug-30-18 08:33AM  Autolus to Present at Upcoming Investor Conferences PR Newswire
Jun-22-18 08:13PM  [$$] Five Drug Startups Reveal Plans to Join Blitz of Biotech IPOs The Wall Street Journal
07:07PM  [$$] Autolus, ElectroCore IPOs Cap Strong Week for Life Sciences The Wall Street Journal
Jun-17-18 04:22PM  The IPO Outlook For The Week Of June 18: Pharma, Pharma And More Pharma Benzinga
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.